| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
| US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
| US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
| US11000567 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
| US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
Vancomycin is owned by Xellia Pharms Aps.
Vancomycin contains Vancomycin.
Vancomycin has a total of 5 drug patents out of which 0 drug patents have expired.
Vancomycin was authorised for market use on 26 August, 2021.
Vancomycin is available in solution;intravenous, oral dosage forms.
Vancomycin can be used as method of treating bacterial infections.
The generics of Vancomycin are possible to be released after 06 November, 2035.
Drugs and Companies using VANCOMYCIN ingredient
Market Authorisation Date: 26 August, 2021
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS, ORAL
VANCOMYCIN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic